基于APRIL配体的BCMA-CAR-T细胞靶向治疗多发性骨髓瘤
研究构建了以BCMA特异性配体APRIL为抗原结合区、4-1BB为共刺激分子的BCMA-CAR-T细胞,体外可特异性杀伤BCMA(+)骨髓瘤细胞系与原代骨髓瘤细胞,并伴脱颗粒和细胞因子释放;小鼠模型中显著延长生存期,提示该策略有望治疗BCMA(+)多发性骨髓瘤。
要点
- BCMA-CAR-T细胞可特异性杀伤BCMA(+)骨髓瘤细胞系和原代骨髓瘤细胞。
- 效靶比1∶4时,BCMA-CAR-T组中BCMA(+)细胞几乎检测不到。
- 小鼠模型中BCMA-CAR-T组中位生存期87.5天,优于空载组67.5天。
核心结论
- 以APRIL为抗原识别区的BCMA-CAR-T细胞有望成为治疗BCMA(+)多发性骨髓瘤的理想策略。
研究设计与样本
- 以BCMA特异性配体APRIL为抗原结合区、4-1BB为共刺激分子构建BCMA-CAR。
- 体外验证BCMA-CAR-T对BCMA(+)骨髓瘤细胞系和原代骨髓瘤细胞的细胞毒作用。
- 构建BCMA(+)骨髓瘤小鼠模型评价BCMA-CAR-T的体内抗肿瘤效应。
主要发现
- 效靶比1∶4时,BCMA-CAR-T细胞组中BCMA(+)细胞几乎检测不到。
- BCMA-CAR-T与空载组T细胞残余细胞比例分别为16.00%和66.85%,P=0.003。
- 与MM1.S、H929、U266共培养脱颗粒水平分别为33.30%对5.62%、16.97%对2.95%、25.87%对2.97%,P值均<0.001。
- 体外伴显著细胞因子释放,P值均<0.01。
- 小鼠中位生存期BCMA-CAR-T组87.5 d、空载组67.5 d,P<0.001。
临床怎么用
- 该研究为BCMA(+)多发性骨髓瘤提供了一种基于APRIL配体识别BCMA的CAR-T策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To construct the BCMA-CAR using the B-cell maturation antigen (BCMA) specific ligand APRIL as antigen binding region and to validate the effect of BCMA-CAR modified T cells (BCMA-CAR-T) on myeloma cells. Methods: The BCMA-CAR was constructed using the BCMA specific ligand APRIL as antigen binding domain and 4-1BB as the costimulatory domain. The specific cytotoxicity against BCMA(+) myeloma cell lines and primary multiple myeloma (MM) cells in vitro were evaluated. In addition, BCMA(+) myeloma xenograft mouse model was established to assess the anti-tumor effect of BCMA-CAR-T cell therapy in vivo. Results: BCMA-CAR-T cells could specifically kill BCMA(+) myeloma cell lines (For BCMA-CAR-T cells, BCMA(+) cells are almost undetectable in the E∶T ratio of 1∶4) and MM patients' bone marrow mononuclear cells (the proportion of residual cells in BCMA-CAR-T and vector-T groups was 16.0% vs 66.85%, P=0.003) with significant degranulation (CAR-T and vector-T cells cocultured with MM1.S, H929 and U266 had degranulation levels of 33.30% vs 5.62%, 16.97% vs 2.95% and 25.87% vs 2.97%, respectively, P<0.001) and cytokines release (P<0.01) in vitro. In a human BCMA(+) myeloma xenograft mouse model, BCMA-CAR-T cells could significantly prolong the survival of mice (The median survival time of mice treated with BCMA-CAR-T and vector-T cells was 87.5 days and 67.5 days, respectively, P<0.001) . Conclusion: The ligand-based BCMA-CAR-T cells could be a promising strategy for BCMA(+) multiple myeloma treatment. 目的: 构建以B细胞成熟抗原(BCMA)的特异性配体APRIL为抗原结合区的BCMA-CAR,并验证该BCMA-CAR修饰的T细胞(BCMA-CAR-T)对多发性骨髓瘤的作用。 方法: 以BCMA的特异性配体APRIL为抗原结合区、4-1BB为共刺激分子而构建BCMA-CAR,体外实验验证BCMA-CAR-T细胞对BCMA(+)骨髓瘤细胞系和原代骨髓瘤细胞的特异性细胞毒作用。此外,构建BCMA(+)骨髓瘤小鼠模型并评价BCMA-CAR-T细胞的体内抗肿瘤效应。 结果: BCMA-CAR-T细胞能特异性杀伤BCMA(+)骨髓瘤细胞系(当效靶比为1∶4时,BCMA-CAR-T细胞组中BCMA(+)细胞几乎检测不到)和骨髓瘤患者的骨髓单个核细胞(BCMA-CAR-T和空载组T细胞的残余细胞比例分别为16.00%和66.85%,P=0.003),并伴随显著的脱颗粒效应(CAR-T和空载组T细胞与MM1.S、H929、U266共培养的脱颗粒水平分别为33.30%对5.62%、16.97%对2.95%、25.87%对2.97%,P值均<0.001)和细胞因子释放(P值均<0.01)。在治疗人BCMA(+)骨髓瘤小鼠移植模型中,BCMA-CAR-T细胞可显著延长小鼠的生存期(BCMA-CAR-T和空载组T细胞治疗小鼠的中位生存期分别为87.5 d、67.5 d,P<0.001)。 结论: 以APRIL为抗原识别区的BCMA-CAR-T细胞有望成为治疗BCMA(+)多发性骨髓瘤的理想策略。.
引用
- Zhong MJ, Xu YX, Xing HY, et al. [Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31775477. doi:10.3760/cma.j.issn.0253-2727.2019.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。